Overview

Price chart · mood · technical indicators

INM

InMed Pharmaceuticals Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$0.7574.33%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$0.58$7.98

Current: $0.75

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

INM

-74.33%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-2.880.0% YoY

Profit margin-170.1%HEALTHCARE

Market cap$2.4MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 0.25
P/S (TTM): 0.53
EV/EBITDA: 0.51

Profitability & growth

ROE (TTM): -97.2%
Operating margin: -258.6%
Revenue growth YoY: -26.2%
Dividend yield: —
Beta: 0.57

Last earnings

Feb 12, 2026 · Reported $-0.51

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About InMed Pharmaceuticals Inc

Company profile

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 885 WEST GEORGIA STREET, VANCOUVER, BC
Fiscal year end: June
Latest quarter: Dec 31, 2025

Market cap$2.4M

Shares outstanding$3.3M

52W high$5.50

52W low$0.58

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

INM

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

InMed Pharmaceuticals Reprices Investment Options to Attract Capital

Sabby, Wainwright option deals reset InMed exercise prices to $0.80

InMed Pharmaceuticals Amends Preferred Investment Options

[8-K] InMed Pharmaceuticals Inc. Reports Material Event

InMed Pharmaceuticals files prospectus supplement for at-the-market share offering

InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement

InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee

InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf

[EFFECT] InMed Pharmaceuticals Inc. SEC Filing

InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance

InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

[8-K] InMed Pharmaceuticals Inc. Reports Material Event

InMed warned by Nasdaq over minimum bid price non-compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharma gets Nasdaq non-compliance notice

InMed has 180 days to lift its stock above $1 and stay on Nasdaq

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC).

About InMed Pharmaceuticals Inc

Classification

Company profile

INM

Market Comparison

INM Market Analysis

Overview

INM

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

InMed Pharmaceuticals Reprices Investment Options to Attract Capital

Sabby, Wainwright option deals reset InMed exercise prices to $0.80

InMed Pharmaceuticals Amends Preferred Investment Options

[8-K] InMed Pharmaceuticals Inc. Reports Material Event

InMed Pharmaceuticals files prospectus supplement for at-the-market share offering

InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement

InMed Pharmaceuticals (NASDAQ: INM) files $1.21M ATM offering with 3.0% fee

InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf

[EFFECT] InMed Pharmaceuticals Inc. SEC Filing

InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance

InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

[8-K] InMed Pharmaceuticals Inc. Reports Material Event

InMed warned by Nasdaq over minimum bid price non-compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharma gets Nasdaq non-compliance notice

InMed has 180 days to lift its stock above $1 and stay on Nasdaq

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Inc recently released positive research data for its Alzheimer's disease treatment project INM-901, according to documents submitted to the U.S. Securities and Exchange Commission (SEC).

About InMed Pharmaceuticals Inc

Classification

Company profile

INM

Market Comparison